Takeda Play

Filtrer videoene per terapiområde

Sikkerhet

The ADZYNMA safety profile was demonstrated in a Phase 3, open-label, crossover trial (NCT03393975), adverse events occurred in 71% of the patients with ADZYNMA.

Artikkel

Mer

Programoversikt

The ADZYNMA clinical development programme included a pivotal, randomised, controlled Phase 3 study, the first of its kind in cTTP patients.

Artikkel

Mer

Dosering

ADZYNMA is an enzyme replacement therapy (ERT) indicated for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Artikkel

Mer

Adzynma hjem

ADZYNMA is an enzyme replacement therapy (ERT) indicated for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Artikkel

Les mer
Subscribe to